DelveInsight’s “Chronic Wounds Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Chronic Wounds pipeline landscapes. It comprises Chronic Wounds pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chronic Wounds therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Chronic Wounds pipeline products.
Some of the key takeaways of the Chronic Wounds Pipeline Report:
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Anterogen, ViroMed BioPharma, Novalead Pharma, Oneness Biotech, MediWound, Tissue Tech/Amniox Medical, Charsire Biotechnology, Energenesis Biomedical, etc., are developing therapies for the treatment of Chronic Wounds.
-
Emerging therapies such as ALLO-ASC-DFU, Engensis, Galnobax, ON101, EscharEx, TTAX01, CSTC1, ENERGI-F703,are expected to have a significant impact on the Chronic Wounds market in the coming years.
-
Galnobax, by Novalead Pharma, has completed a global Phase I/II clinical trial in DFU successfully meeting both primary and secondary endpoints for both safety and efficacy. The company is investigating it in the Phase III clinical trial.
Get an overview of pipeline landscape @ Chronic Wounds Clinical Trials Analysis
A chronic wound is a wound that does not heal in an orderly set of stages and in a predictable amount of time the way most wounds do; wounds that do not heal within three months are often considered chronic.
-
Galnobax by Novalead Pharma
Galnobax, by Novalead Pharma, is a topical gel of Esmolol hydrochloride for the treatment of hard to heal diabetic foot ulcers. It is a repurposed generic drug molecule, which has completed a global Phase I/II clinical trial in DFU successfully meeting both primary and secondary endpoints for both safety and efficacy.
-
Engensis by ViroMed BioPharma
Engensis(VM202) is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms needed for optimal therapeutic benefits.
-
ON101 by Oneness Biotech
Oneness Biotech is also coming up with its new botanical drug ointment, ON101. Clinical studies demonstrated that ON101 has significant therapeutic effects on wound healing and could reduce scar formation.
-
TTAX01 by Tissue Tech
One Pharma Company named Tissue Tech, which is developing a product TTAX01 for the management of venous leg ulcers and non healing wounds.
-
EscharEx by MediWound
Another topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds is being developed by MediWound, named EscharEx. It is a mixture of proteolytic enzymes for the management of debridement in chronic and other hard-to-heal wounds
Scope of Chronic Wounds Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Anterogen, ViroMed BioPharma, Novalead Pharma, Oneness Biotech, MediWound, Tissue Tech/Amniox Medical, Charsire Biotechnology, Energenesis Biomedical, and others.
-
Pipeline Therapies: ALLO-ASC-DFU, Engensis, Galnobax, ON101, EscharEx, TTAX01, CSTC1, ENERGI-F703, and others.
Table of Contents:
|
1 |
Chronic Wounds Report Introduction |
|
2 |
Chronic Wounds Executive Summary |
|
3 |
Chronic Wounds Overview |
|
4 |
Chronic Wounds- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Chronic Wounds Pipeline Therapeutics |
|
6 |
Chronic Wounds Late Stage Products (Phase II/III) |
|
7 |
Chronic Wounds Mid Stage Products (Phase II) |
|
8 |
Chronic Wounds Early Stage Products (Phase I) |
|
9 |
Chronic Wounds Preclinical Stage Products |
|
10 |
Chronic Wounds Therapeutics Assessment |
|
11 |
Chronic Wounds Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Chronic Wounds Key Companies |
|
14 |
Chronic Wounds Key Products |
|
15 |
Chronic Wounds Unmet Needs |
|
16 |
Chronic Wounds Market Drivers and Barriers |
|
17 |
Chronic Wounds Future Perspectives and Conclusion |
|
18 |
Chronic Wounds Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Related Reports:
DelveInsight’s Chronic Wounds – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Chronic Wounds, historical and forecasted epidemiology as well as the Chronic Wounds market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s Chronic Wounds – Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Chronic Wounds epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/